medcelerator · clinician one-pager
Once-Weekly Basal Insulin Shot for Adults with Type 2 Diabetes
Onswik (insulin efsitora alfa-gobe) — once-weekly basal insulin for adults with type 2 diabetes
FDA Approved · United States, European Union · September 25, 2026
Condition: Type 2 Diabetes
Who this is for
This is for adults with type 2 diabetes — and caregivers helping them — who may be candidates for a once-weekly basal insulin instead of a daily basal shot. It explains FDA approval of Onswik (insulin efsitora alfa-gobe) on 23 September 2026 (USPI Revised 09/2026), the EU marketing authorisation of 20 August 2026, how QWINT-1–4 showed non-inferior A1C versus daily glargine or degludec, U-500 / U-1,000 KwikPen dosing honesty, and why this is a different label from Awiqli (insulin icodec) — without treating Onswik as type 1 insulin, mixing pens, or assuming every country has funded supply. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States and the European Union, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-once-weekly-insulin-type-2-diabetes-mellitus
European Union · Prescription
EU prescription (EC marketing authorisation)
https://www.ema.europa.eu/en/medicines/human/EPAR/onswik
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
CTIS (EU Clinical Trials Information System)
European Union public portal for clinical trials submitted under the Clinical Trials Regulation. Search by medicine, condition, and member state. A CTIS record is not an EMA marketing authorisation and is not enrolment.
https://euclinicaltrials.eu/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/onswik-insulin-efsitora